中国基层医药
中國基層醫藥
중국기층의약
Chinese Journal of Primary Medicine and Pharmacy
2015年
21期
3314-3316,3317
,共4页
重复经颅磁刺激%舍曲林%帕金森病%抑郁
重複經顱磁刺激%捨麯林%帕金森病%抑鬱
중복경로자자격%사곡림%파금삼병%억욱
Repetitive transcranial magnetic stimulation%Setraline%Parkinson's disease%Deppression
目的：探讨重复经颅磁刺激联合舍曲林治疗帕金森后抑郁的疗效。方法将80例帕金森后抑郁患者按数字表法随机分为研究组、对照组，每组40例。对照组单用舍曲林治疗，研究组采用重复经颅磁刺激联合舍曲林治疗，两组患者均治疗4周。于治疗前及治疗后1、2、4周分别评定汉密尔顿抑郁量表（HAMD）、帕金森病统一评分量表（UPDRS）及副反应量表（TESS）评分，比较两组临床疗效。结果研究组治疗后2、4周 HAMD 评分分别为（18．44±5．56）分、（10．51±4．27）分，均明显低于对照组的（21．23±5．18）分、（14．05±4．10）分（t2周＝-2．322，t4周＝－3．782，均 P ＜0．05）；研究组治疗后2、4周 UPDRS 量表得分分别为（30．14±4．92）分、（28．39±3．38）分，均明显低于对照组的（33．74±4．87）分、（31．09±3．94）分（t2周＝－3．289，t4周＝－3．290，均 P ＜0．05）；研究组临床显效率为77．5％，明显高于对照组的45．0％（χ2＝4．450， P ＜0．05）。结论重复经颅磁刺激联合舍曲林治疗帕金森后抑郁的疗效优于单用舍曲林。
目的：探討重複經顱磁刺激聯閤捨麯林治療帕金森後抑鬱的療效。方法將80例帕金森後抑鬱患者按數字錶法隨機分為研究組、對照組，每組40例。對照組單用捨麯林治療，研究組採用重複經顱磁刺激聯閤捨麯林治療，兩組患者均治療4週。于治療前及治療後1、2、4週分彆評定漢密爾頓抑鬱量錶（HAMD）、帕金森病統一評分量錶（UPDRS）及副反應量錶（TESS）評分，比較兩組臨床療效。結果研究組治療後2、4週 HAMD 評分分彆為（18．44±5．56）分、（10．51±4．27）分，均明顯低于對照組的（21．23±5．18）分、（14．05±4．10）分（t2週＝-2．322，t4週＝－3．782，均 P ＜0．05）；研究組治療後2、4週 UPDRS 量錶得分分彆為（30．14±4．92）分、（28．39±3．38）分，均明顯低于對照組的（33．74±4．87）分、（31．09±3．94）分（t2週＝－3．289，t4週＝－3．290，均 P ＜0．05）；研究組臨床顯效率為77．5％，明顯高于對照組的45．0％（χ2＝4．450， P ＜0．05）。結論重複經顱磁刺激聯閤捨麯林治療帕金森後抑鬱的療效優于單用捨麯林。
목적：탐토중복경로자자격연합사곡림치료파금삼후억욱적료효。방법장80례파금삼후억욱환자안수자표법수궤분위연구조、대조조，매조40례。대조조단용사곡림치료，연구조채용중복경로자자격연합사곡림치료，량조환자균치료4주。우치료전급치료후1、2、4주분별평정한밀이돈억욱량표（HAMD）、파금삼병통일평분량표（UPDRS）급부반응량표（TESS）평분，비교량조림상료효。결과연구조치료후2、4주 HAMD 평분분별위（18．44±5．56）분、（10．51±4．27）분，균명현저우대조조적（21．23±5．18）분、（14．05±4．10）분（t2주＝-2．322，t4주＝－3．782，균 P ＜0．05）；연구조치료후2、4주 UPDRS 량표득분분별위（30．14±4．92）분、（28．39±3．38）분，균명현저우대조조적（33．74±4．87）분、（31．09±3．94）분（t2주＝－3．289，t4주＝－3．290，균 P ＜0．05）；연구조림상현효솔위77．5％，명현고우대조조적45．0％（χ2＝4．450， P ＜0．05）。결론중복경로자자격연합사곡림치료파금삼후억욱적료효우우단용사곡림。
Objective To explore the efficacy of low -frequency repetitive transcranial magnetic stimulation (rTMS)and setraline in treating Parkinson's disease patients with depression.Methods 80 cases of Parkinson's dis-ease with depression were randomly divided into the study group(administered with rTMS and setraline)and the con-trol group(administered only with setraline)according to random number table,40 cases in each group.Hamilt De-pression Rating Scale(HAMD),Unified Parkinson's Disease Rating Scale(UPDRS)and Treatment Emergent Symp-toms Scale(TESS)were assessed before treatment and 1,2,4 weeks after treatment.Results The scores of HAMD and UPDRS in the study group were lower than those in the control group[the score of HAMD at 2nd week in the study group was (18.44 ±5.56 )points,the score of HAMD at 4th week in the study group was (10.51 ± 4.27)points,the score of HAMD at 2nd week in the control group was (21.23 ±5.18)points,the score of HAMD at 4th week in the control group was (14.05 ±4.10)points,t2w =-2.322,t4w =-3.782,all P <0.05],and the score of UPDRS at 2nd week in the study group was (30.14 ±4.92)points,the score of HAMD at 4th week in the study group was (28.39 ±3.38)points,the score of UPDRS at 2nd week in the control group was (33.74 ±4.87)points, the score of HAMD at 4th week in the control group was (31.09 ±3.94)points (t2w =-3.289,t4w =-3.290,all P <0.05),while the effective rate of the study group(77.5%)was significantly higher than that in the control group (45.0%)(χ2 =4.450,P <0.05 ).Conclusion The efficacy of rTMS combined with setraline for Parkinson 's disease with depression is superior to that of using setraline alone.
